Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

By sjmartinez • May 29, 2025

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Wang A, Dubrovsky L, Llovet JM. Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma. ESMO Open. 2025 May 27;10(6):105065. doi: 10.1016/j.esmoop.2025.105065. Epub ahead of print. PMID: 40435872.

A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck

Henson C, Clayburgh D, Lee A, Wong D, Kudrimoti M, Lee S, Kalman N, Rao K, Sohn KY, Crawford J, Villa A, Sonis S. A[...]

Basic rules to respond to PD-1 blockade cancer immunotherapy

Ribas A. Basic rules to respond to PD-1 blockade cancer immunotherapy. J Immunother Cancer. 2025 May 26;13(5):e012096. doi: 10.1136/jitc-2025-012096. PMID: 40425230.

Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma

Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu[...]